From The Lab: Weight Loss Drug SRT1720

The SRT1720 drug was specifically designed to hit the SIRT1 protein. The health effects are enormous.

Warning: include(/is/htdocs/wp1012443_ZNG8CQAE3E/www/losew.com//manydoms/losew/inc/adsense-1.php) [function.include]: failed to open stream: No such file or directory in /is/htdocs/wp1012443_ZNG8CQAE3E/www/losew.com/weight-loss-supplements/drugs/SRT1720/index.php on line 39

Warning: include() [function.include]: Failed opening '/is/htdocs/wp1012443_ZNG8CQAE3E/www/losew.com//manydoms/losew/inc/adsense-1.php' for inclusion (include_path='.:/usr/share/pear/php5') in /is/htdocs/wp1012443_ZNG8CQAE3E/www/losew.com/weight-loss-supplements/drugs/SRT1720/index.php on line 39

This is coming directly from the laboratories. Researcher's found a drug they call SRT1720. It acts through a protein called SIRT1. Taking the SRT1720 drug enhances running endurance and prevents you from gaining weight and makes you resistant for insulin even when you are on a high-fat diet.

How does SRT1720 work? According to several science publications, SRT1720 works by shifting the metabolism to a fat-burning mode that normally takes over only when energy levels are low.

What can SRT1720 be used for? It looks like with the help of SRT1720, SIRT1 becomes the top tool for fighting health endangering metabolic disorders like obesity or type 2 diabetes.

What makes SRT1720 so special? - The researchers found that the major advantage of the SRT1720 drug or any other activator of SIRT1 over resveratrol is, that it is likely to come with fewer side effects. These occurred only at very high doses. At this point, further studies are needed to learn more about the side-effects and when they occur..

All the information above were publicly released on 4-Nov-2008. The press release can be found here: EurekAlert - SRT1720

SRT1720 Resources: You can find out more on this miracle weight loss drug at Science Daily and SRT1720.com, which is the official website, where also the metabolic benefits of Resveratrol (ingredient in red wine) on SIRT1 are discussed.

Researchers involved in the work on SRT1720: From the Institut de Genetique et de Biologie Moleculaire et Cellulaire, CNRS/ INSERM/ Universite´ Louis Pasteur, Illkirch in France, there are:
Jerome N. Feige, Marie Lagouge, Carles Canto, Johan Auwerx, Chikage Mataki and Axelle Strehle.

From the University of Amsterdam in the Netherlands there is: Sander M. Houten.

From the the Sirtris Pharmaceuticals Incorporaion in Cambridge, MA, United States of America there are: Jill C. Milne, Philip D. Lambert and Peter J. Elliott